Every 10-Q that Qualigen Therapeutics Inc (QLGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow QLGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QLGN filings page.
AIxCrypto Holdings, Inc. reported a larger net loss and rising liquidity risk for the three months ended March 31, 2026, while accelerating its shift toward a crypto-focused treasury strategy.
The company recorded a net loss of $6,079,016, more than double the prior-year period, with total operating expenses of $4,333,721 and an additional $1,945,582 net loss on digital assets. Cash and cash equivalents fell from $19,332,707 at December 31, 2025 to $6,201,121, driven by $4,495,354 used in operating activities and $8,504,232 used in investing, including a $10,000,000 related-party prepaid investment to acquire Faraday Future shares and significant crypto purchases.
As of March 31, 2026, the company held digital assets with a fair value of $6,197,267 against a cost basis of $10,433,028, reflecting substantial unrealized losses, and carried a short-term note receivable from Marizyme of $5,083,002 with an allowance for credit losses of $4,697,574. Stockholders’ equity declined to $21,871,593, while accumulated deficit reached $146,106,466. Management explicitly raised substantial doubt about the company’s ability to continue as a going concern, citing the lack of revenues, ongoing cash burn, dependence on digital assets, and the absence of committed new financing.
Qualigen Therapeutics, Inc. reported a net loss of $2.0 million for the quarter and $6.4 million for the nine months ended September 30, 2025, modestly higher than the prior year. The company’s balance sheet changed significantly after equity financings, with cash and cash equivalents rising to $38.8 million and total assets to $43.5 million, compared with $4.7 million of assets at year-end 2024.
In September 2025, Qualigen closed a $41.0 million Subscription Agreement led by Faraday Future, issuing common stock and new Series B convertible preferred stock. Up to $6.8 million of net proceeds are designated for existing debt repayment and current operations, while the remaining cash and contributed currency are reserved for establishing cryptocurrency treasury operations. Despite the capital raise, recurring losses, limited operating cash, and the early-stage nature of the new crypto strategy led management to conclude there is substantial doubt about the company’s ability to continue as a going concern over the next year.
Qualigen Therapeutics, Inc. (QLGN) reported a challenging quarter with limited cash and ongoing operating losses. The company had approximately $332,000 in cash and an accumulated deficit of $127.4 million. For the six months ended June 30, 2025 the company used $2.7 million in operating cash and $6.3 million for the year ended December 31, 2024. Loss from continuing operations was $4.33 million for the period versus $3.51 million in the prior comparative period. Short-term borrowings included $3.64 million from nine investors and additional promissory notes totaling $2.3 million. Subsequent to period end, the company closed a private placement in July 2025 raising net proceeds of $4.258 million, which management expects will provide liquidity through year-end. The filing discloses multiple convertible debentures, warrant re-pricings, preferred stock conversions, a 2024 reverse stock split, and a $468,000 loan loss reserve related to Marizyme notes.